Key result
Selective serotonin reuptake inhibitors safely and effectively treat depression and anxiety in patients with cardiovascular disease, and may improve survival after myocardial infarction.
Why the study?
Do selective serotonin reuptake inhibitors improve psychiatric morbidity and cardiovascular outcomes in patients with cardiovascular disease?
Systematic Review
Do selective serotonin reuptake inhibitors improve psychiatric morbidity and cardiovascular outcomes in patients with cardiovascular disease?
This review discusses the safety and efficacy of antidepressants, particularly SSRIs, for treating anxiety and depression in patients with cardiovascular disease.
SSRIs may be used cautiously for psychiatric symptoms in CVD; leaves open effects on cardiovascular outcomes.
What role do selective serotonin reuptake inhibitors have in treating psychiatric morbidity in patients with cardiovascular disease? This review discusses the safety and efficacy of various antidepressants in this group of patients and their potential for improving cardiovascular outcomes
No takes yet. Share an insight, caveat, or question.
Davies et al. (2004) conducted a systematic review in Cardiovascular disease with comorbid anxiety and depressive disorders. Selective serotonin reuptake inhibitors (SSRIs) vs. Placebo or tricyclic antidepressants was evaluated. Selective serotonin reuptake inhibitors safely and effectively treat depression and anxiety in patients with cardiovascular disease, and may improve survival after myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: